FMP
Eloxx Pharmaceuticals, Inc.
ELOX
OTC
Eloxx Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on developing ribosome modulation for the treatment of rare and ultra-rare premature stop codon diseases. Its lead investigational drug product candidate is ELX-02, which is in Phase 2 clinical trial for the treatment of cystic fibrosis and nephropathic cystinosis patients with diagnosed nonsense mutations. The company also develops various preclinical programs for the treatment of alport syndrome, recessive dystrophic epidermolysis bullosa, junctional epidermolysis bullosa, and familial adenomatous polyposis, as well as various earlier discovery stage programs in oncology. Eloxx Pharmaceuticals, Inc. was founded in 2013 and is headquartered in Watertown, Massachusetts.
0.0001 USD
3.0000000015651188e-12 (0.000003%)
ELOX Financial Statements
Year
2022
2021
2020
2019
CF from Operating Activities
-31.84M
-35M
-28.17M
-39.39M
Net Income
-36.06M
-66.73M
-34.58M
-50.87M
Depreciation & Amortization
695k
960k
571k
559k
Deferred Income Taxes
81k
-456k
15k
-303k
Stock Based Compensation
3.02M
9.17M
8.67M
11.34M
Change in Working Capital
-118k
-32k
-3.4M
-644k
Accounts Receivable
0
0
0
0
Inventory
0
0
0
0
Accounts Payable
1.64M
-320k
-1.39M
1.12M
Other Working Capital
-1.76M
288k
-2.01M
-1.77M
Other Non-Cash Items
541k
22.09M
563k
535k
CF from Investing Activities
-66k
2.06M
33.79M
-33.52M
Investments in Property, Plant & Equipment
-66k
-89k
0
-40k
Net Acquisitions
0
2.15M
0
2k
Investment Purchases
0
0
0
-67.21M
Sales/Maturities of Investments
0
0
33.75M
33.75M
Other Investing Activites
0
0
42k
-22k
CF from Financing Activities
8.81M
50.79M
-3.44M
46.8M
Debt Repayment
0
-11.38M
-4.58M
-15M
Common Stock Issued
0
47.72M
0
32.88M
Common Stock Repurchased
0
0
0
0
Dividends Paid
0
0
0
0
Other Financing Activites
8.81M
2.58M
348k
-1.08M
Free Cash Flow
-31.91M
-35.09M
-28.17M
-39.43M
Operating Cash Flow
-31.84M
-35M
-28.17M
-39.39M
Capital Expenditures
-66k
-89k
0
-40k
Cash at Beginning of Period
42.57M
24.72M
22.54M
48.65M
Cash at End of Period
19.47M
42.57M
24.72M
22.54M
Net Change In Cash
-23.1M
17.84M
2.19M
-26.11M
Retained Earning Schedule
Year
2022
2021
2020
2019
Retained Earnings (Previous Year)
-238.32M
-171.6M
-137.02M
-86.14M
Net Income
-36.06M
-66.73M
-34.58M
-50.87M
Stock Repurchases
0
0
0
0
Dividend Paid
0
0
0
0
Retained Earnings
-274.39M
-238.32M
-171.6M
-137.02M
Other Distributions
-36.06M
-66.73M
-34.58M
-50.87M
PPE Schedule
Year
2022
2021
2020
2019
Gross PPE
994k
1.66M
554k
1.13M
Annual Depreciation
695k
960k
571k
559k
Capital Expenditure
-66k
-89k
0
-40k
Net PPE
365k
788k
-17k
606k
Intangible and Goodwill Schedule
Year
2022
2021
2020
2019
Acquisitions and Adjustments
0
0
0
0
Goodwill (Previous Year)
0
0
0
0
Goodwill
0
0
0
0
All figures are in USD.
